MAP4: Potential Drug Targets (G4134)

Target Name: MAP4

NCBI ID: G4134

MAP4

MAP4: Potential Drug Targets

MAP4, also known as Microtubule associated protein 4, is a protein that is expressed in a wide range of tissues and cells in the human body. It is a key component of microtubules, which are the protein structures that form the framework of the mitotic spindle, which pulls the sister chromatids apart during cell division.

MAP4 is a 21-kDa protein that is expressed in most tissues of the body, including muscle, brain, heart, and liver. It is highly conserved across different species, and its sequence is highly conserved between humans and other organisms.

MAP4 is involved in many different cellular processes in the cell, including cell division, intracellular transport, and cell signaling. It is a key regulator of mitosis, and it is involved in the formation of the mitotic spindle, which is a critical structure that pulls the sister chromatids apart during cell division. It is also involved in the regulation of actin filaments, which are important for cell signaling and cytoskeletal organization.

MAP4 is a protein that has been identified as a potential drug target in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its high conservation sequence and its involvement in multiple cellular processes make it an attractive target for drug development.

One of the reasons why MAP4 is considered a potential drug target is its involvement in cancer.MAP4 has been shown to be involved in the regulation of cell cycle progression, which is a critical step in the development of cancer. It is also involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed in tumors.

Studies have shown that MAP4 is highly expressed in many types of cancer, including breast, ovarian, and prostate cancers. It is also involved in the regulation of cell adhesion, which is a critical step in the development of cancer cells.

Another potential drug target for MAP4 is its involvement in neurodegenerative diseases.MAP4 has been shown to be involved in the regulation of neurotransmitter release from neurons, which is important for normal brain function. It is also involved in the regulation of glial cells, which are important for the support of nerve cells.

Studies have shown that MAP4 is involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. It is also involved in the regulation of neurotransmitter release from neurons, which is a critical step in the development of neurodegenerative diseases.

MAP4 is also a potential drug target for autoimmune disorders.MAP4 has been shown to be involved in the regulation of immune cell function, which is important for the development of autoimmune disorders.

Studies have shown that MAP4 is involved in the regulation of immune cell function, which is important for the development of autoimmune disorders. It is also involved in the regulation of inflammation, which is a critical step in the development of many autoimmune disorders.

In conclusion, MAP4 is a protein that is involved in many different cellular processes in the cell, including cell division, intracellular transport, and cell signaling. It is a key regulator of mitosis and the formation of the mitotic spindle, and it is also involved in the regulation of cell cycle progression, angiogenesis, neurotransmission, and inflammation. Its high conservation sequence and its involvement in multiple cellular processes make it an attractive target for drug development. The potential drug targets for MAP4 include cancer, neurodegenerative diseases, and autoimmune disorders.

Protein Name: Microtubule Associated Protein 4

Functions: Non-neuronal microtubule-associated protein. Promotes microtubule assembly

The "MAP4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAP4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets